Vistagen Therapeutics, Inc.
VTGN· Nasdaq
VTGNVistagen Therapeutics, Inc.
Filed Jun 15, 2026 · 10-K · 76 days after period end · 0001628280-26-043271
derived · Computed from the longer spans the company filed.
| Metric | Q4 2026dderived from reported figures | Q4 2025dderived from reported figures | Q4 2024dderived from reported figures | Q4 2023 |
|---|---|---|---|---|
| Revenue | $464.00K | — | $198.00K | $176.00K |
| Net Income | -$16.27M | -$13.64M | -$9.52M | -$12.23M |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Vistagen Therapeutics, Inc. · CIK 1411685 · Engraved from SEC EDGAR
ended Mar 31, 2026 · filed Jun 15, 2026 · 76 d after period end
